Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models
Heterogeneity in Alzheimer's disease progression contributes to the ongoing failure to demonstrate efficacy of putative disease-modifying therapeutics that have been trialed over the past two decades. Any treatment effect present in a subgroup of trial participants (responders) can be diluted b...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |